BrainStorm Cell Therapeutics Inc. To Host Conference Call To Discuss Final Results Of Phase 2a Trial Of NurOwna In ALS On January 5, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, will release the final results from its phase 2a clinical trial of NurOwn in amytrophic lateral sclerosis and hold a conference call and webcast to discuss the data on , MD, PhD, stated, "We are very excited to share the final results of this study.
http://ift.tt/1zpaMDF
http://ift.tt/1zpaMDF
No comments:
Post a Comment